This month

BPC-157's origin story reached STAT News and the FDA calendar in the same summer

The most-searched recovery peptide on the internet just got two things at once: a STAT News investigation and a federal hearing date. On June 1, STAT News published a [profile of Predrag Sikiric](https://www.statnews.com/2026/06/01/bpc-157-researcher-predrag-sikiric-addesses-skeptics-questions/) — the 72-year-old University of Zagreb pharmacologist who first conceived BPC-157 in 1975 as a second-year medical student and spent the following five decades collecting gastric juice from clinics and slaughterhouses to isolate it. On July 23, the FDA's Pharmacy Compounding Advisory Committee is scheduled to convene at its White Oak campus in Silver Spring, Maryland, and BPC-157 is on the agenda. The committee will decide whether licensed compounding pharmacies should be permitted to prepare it for patient-specific prescriptions — a question the peptide market has been trying to answer with warehouse raids and DOJ prosecutions for years while the Zagreb lab quietly published animal studies. Seven days from now, on June 30, the window for oral presentation requests to the PCAC closes. Written public comments are due July 9. After 50 years, the molecule is finally in a room with federal regulators — and the source trail looks the same as it did in 1989: almost entirely animal research.

The actual biology

A 15-amino-acid fragment from gastric juice — and a property claim a chemist just questioned publicly

BPC-157 is a pentadecapeptide — 15 amino acids, sequence GEPPPGKPADDAGLV — that Sikiric's team isolated from human gastric juice and designated Body Protection Compound 157. The mechanism story centers on tissue repair signaling: BPC-157 is proposed to stimulate angiogenesis (new blood vessel formation), modulate inflammatory cytokine activity, and activate pathways linked to cellular survival and tissue remodeling. The biological frame is plausible. Angiogenesis and inflammation suppression are real targets in wound healing; the pathway-level rationale behind much of the animal work is mechanistically coherent. What is less settled is the origin claim. STAT News reported that chemist Anna Mapp raised a specific concern: BPC-157's precise genetic sequence does not appear in the human genome or the human microbiome. That matters because Sikiric has long described it as a natural gastric substance the body already produces. [The PubMed literature on BPC-157](https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157) runs to several hundred papers — but the authorship pattern is notable: the overwhelming majority comes from one laboratory in Zagreb.

The public claim

Tendons, gut, brain — the internet assigned BPC-157 to every injury category that lacks a good drug

BPC-157 generates 73,400 monthly searches and has become the default peptide that gym culture recommends when someone asks about tendon injuries, leaky gut, and more recently traumatic brain injury recovery. The standard forum summary is clean: it is the repair peptide the body already makes, available in a form that can be supplemented. Athletes discuss it alongside TB-500 as the standard two-peptide protocol for soft-tissue problems. Biohacker communities have added gut-lining support and neurological recovery to the claim stack. The compounding ban that ran from 2023 through early 2026 did not quiet the conversation — it drove it to unregulated online suppliers and telehealth clinics operating against uncertain supply chains. The result is a peptide with extremely high internet familiarity, a coherent (if mostly animal-derived) mechanism story, and a marketing ecosystem built on claims the clinical record cannot yet support. The gap between 'a gastric peptide the body already produces' and 'a proven human tissue repair drug' is 50 years of animal research that has not crossed into controlled human trials.

What the data says

Hundreds of animal studies from one laboratory — and the pharmaceutical program that GSK walked away from

The BPC-157 animal literature is unusually large for an unapproved research peptide. [The PubMed record for BPC-157](https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157) includes several hundred papers, the bulk produced by Sikiric's group at the University of Zagreb across tendons, soft tissue, the nervous system, the gut, and cardioprotective signaling in rodent and rabbit models. These papers are not fabrications — the Zagreb lab has produced consistent findings across animal injury models for decades. The scientific question is translation: does a peptide that accelerates tendon repair in rats, modulates gut inflammation in rabbits, and shows neuroregenerative effects in mice produce the same results in injured humans at clinically meaningful doses? No completed, peer-reviewed human trial has answered that question. [ClinicalTrials.gov records for BPC-157](https://clinicaltrials.gov/search?term=BPC-157) show a thin registration footprint relative to the molecule's search volume. PLIVA, the Croatian pharmaceutical company that partnered with Sikiric, advanced the compound toward clinical investigation; GSK acquired PLIVA's research institute in 2006 and exited the program. Sikiric recovered the licensing rights in 2009. A large pharmaceutical company walking away from a compound after acquisition is part of the source trail for why five decades of Zagreb data have not produced a licensed drug.

Animal / preclinical — PeptideFactCheck stance

The July 23 hearing changes compounding access — it does not add human evidence

BPC-157 holds the Animal / preclinical evidence tier on PeptideFactCheck — mechanistically interesting, not clinically settled. The tier is precise here. The mechanism rationale is coherent, the animal data is unusually extensive by research-peptide standards, and the molecule's origin in gastric biology gives it a more concrete starting point than many compounds in this category. What the tier reflects is the absence of clinical evidence: no peer-reviewed randomized controlled trial has validated the recovery, gut-lining, or neurological claims that drive 73,400 monthly searches. The [FDA's bulk drug compounding safety framework](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) is evaluating whether licensed pharmacies can compound BPC-157 under the 503A pathway — a manufacturing and pharmacy-access question, not a clinical validation of 50 years of Zagreb research. A positive PCAC vote on July 23 would change the compounding calendar. It would not close the gap between the rat study and the human randomized trial. Predrag Sikiric is 72 and still in Zagreb. The oral comment window to the FDA closes in seven days. In June 2026, after half a century, the molecule finally has a federal audience. The human evidence has not arrived.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.